Full Press Release Details
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that a late-breaking abstract featuring updated clinical data from the Phase 1/2 TARGET-D-101 study of VS-7375 in previously treated patients with KRAS G12D-mutated metastatic non-small cell lung cancer (NSCLC) has been selected for oral presentation at the IASLC/ASCO 2026 North America Conference on Lung C